Andrew D Krystal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5603450/publications.pdf

Version: 2024-02-01

231 papers

16,631 citations

14655 66 h-index 120 g-index

235 all docs

235 docs citations

times ranked

235

12856 citing authors

#	Article	IF	CITATIONS
1	Randomized controlled trial of digital cognitive behavior therapy for prenatal insomnia symptoms: effects on postpartum insomnia and mental health. Sleep, 2022, 45, .	1.1	29
2	Links between the brain and body during sleep: implications for memory processing. Trends in Neurosciences, 2022, 45, 212-223.	8.6	7
3	Trajectories of Insomnia in Adults After Traumatic Brain Injury. JAMA Network Open, 2022, 5, e2145310.	5.9	12
4	Telemedicine-delivered cognitive-behavioral therapy for insomnia in alcohol use disorder (AUD): study protocol for a randomized controlled trial. Trials, 2022, 23, 59.	1.6	4
5	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry, 2022, 27, 1286-1299.	7.9	68
6	Examining Experiences of Poor Sleep During Pregnancy: A Qualitative Study to Inform the Development of a Prenatal Sleep Intervention. Global Advances in Health and Medicine, 2022, 11, 2164957X2210876.	1.6	7
7	Overnight Delta Dynamics Associated with Daytime Psychomotor Performance in Adults with Insomnia and Healthy Controls. Nature and Science of Sleep, 2022, Volume 14, 217-230.	2.7	4
8	Cost-effectiveness of digital cognitive behavioral therapy (<i>Sleepio</i>) for insomnia: a Markov simulation model in the United States. Sleep, 2021, 44, .	1.1	26
9	Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexpiprazole: An open-label, flexible-dose, exploratory substudy. Journal of Affective Disorders, 2021, 278, 288-295.	4.1	1
10	Mutations in Metabotropic Glutamate Receptor 1 Contribute to Natural Short Sleep Trait. Current Biology, 2021, 31, 13-24.e4.	3.9	25
11	Blinding and bias in a hypnotic clinical trial. Human Psychopharmacology, 2021, 36, 1-5.	1.5	1
12	State-dependent responses to intracranial brain stimulation in a patient with depression. Nature Medicine, 2021, 27, 229-231.	30.7	123
13	Optimizing computation of overnight decline in delta power: Evidence for slower rate of decline in delta power in insomnia patients. Clinical Neurophysiology, 2021, 132, 545-553.	1.5	6
14	Evaluating lemborexant for the treatment of insomnia. Expert Opinion on Pharmacotherapy, 2021, 22, 1235-1243.	1.8	3
15	A Longitudinal Study to Assess Antidepressant Treatment Patterns and Outcomes in Individuals with Depression in the General Population. CNS Spectrums, 2021, 26, 180-180.	1,2	1
16	Challenges in Managing Insomnia in Older People. Journal of Clinical Psychiatry, 2021, 82, .	2.2	0
17	Association of Sleep and β-Amyloid Pathology Among Older Cognitively Unimpaired Adults. JAMA Network Open, 2021, 4, e2117573.	5.9	27
18	Optimizing Treatment for Insomnia. Journal of Clinical Psychiatry, 2021, 82, .	2.2	2

#	Article	IF	CITATIONS
19	Design of the national adaptive trial for PTSD-related insomnia (NAP study), VA cooperative study program (CSP) #2016. Contemporary Clinical Trials, 2021, 109, 106540.	1.8	O
20	Distributed Subnetworks of Depression Defined by Direct Intracranial Neurophysiology. Frontiers in Human Neuroscience, 2021, 15, 746499.	2.0	6
21	Closed-loop neuromodulation in an individual with treatment-resistant depression. Nature Medicine, 2021, 27, 1696-1700.	30.7	212
22	Sleep therapeutics and neuropsychiatric illness. Neuropsychopharmacology, 2020, 45, 166-175.	5.4	25
23	Pilot Study of An Intracranial Electroencephalography Biomarker of Depressive Symptoms in Epilepsy. Journal of Neuropsychiatry and Clinical Neurosciences, 2020, 32, 185-190.	1.8	10
24	Omitted Conflict of Interest Disclosures. JAMA Psychiatry, 2020, 77, 768.	11.0	1
25	Is cellular energy monitoring more responsive to hypoxia than pulse oximetry?. Sleep and Breathing, 2020, 24, 1633-1643.	1.7	0
26	Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology, 2020, 45, 1656-1663.	5.4	50
27	A randomized proof-of-mechanism trial applying the  fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nature Medicine, 2020, 26, 760-768.	30.7	129
28	Effectiveness of Sequential Psychological and Medication Therapies for Insomnia Disorder. JAMA Psychiatry, 2020, 77, 1107.	11.0	49
29	Efficacy of Digital Cognitive Behavioral Therapy for the Treatment of Insomnia Symptoms Among Pregnant Women. JAMA Psychiatry, 2020, 77, 484.	11.0	109
30	Content validity of a sleep numerical rating scale and a sleep diary in adults and adolescents with moderate-to-severe atopic dermatitis. Journal of Patient-Reported Outcomes, 2020, 4, 100.	1.9	13
31	Feasibility and Acceptability of Wearable Sleep Electroencephalogram Device Use in Adolescents: Observational Study. JMIR MHealth and UHealth, 2020, 8, e20590.	3.7	9
32	An exploratory analysis of the association of circadian rhythm dysregulation and insomnia with suicidal ideation over the course of treatment in individuals with depression, insomnia, and suicidal ideation. Journal of Clinical Sleep Medicine, 2020, 16, 1311-1319.	2.6	23
33	Longitudinal study of narcolepsy symptoms in first, second, and third-degree relatives of simplex and multiplex narcolepsy families. Sleep Medicine, 2019, 53, 88-93.	1.6	4
34	British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. Journal of Psychopharmacology, 2019, 33, 923-947.	4.0	173
35	Sleep Pharmacogenetics. Sleep Medicine Clinics, 2019, 14, 317-331.	2.6	5
36	The assessment and management of insomnia: an update. World Psychiatry, 2019, 18, 337-352.	10.4	107

#	Article	IF	Citations
37	A Rare Mutation of Î ² 1-Adrenergic Receptor Affects Sleep/Wake Behaviors. Neuron, 2019, 103, 1044-1055.e7.	8.1	54
38	Reducing Suicidal Ideation Through Insomnia Treatment (REST-IT): A Randomized Clinical Trial. American Journal of Psychiatry, 2019, 176, 957-965.	7.2	103
39	Prevalence of obstructive sleep apnea in suicidal patients with major depressive disorder. Journal of Psychiatric Research, 2019, 116, 147-150.	3.1	18
40	An Electrophysiological Biomarker That May Predict Treatment Response to ECT. Journal of ECT, 2019, 35, 95-102.	0.6	10
41	Circadian Preference as a Moderator of Depression Outcome Following Cognitive Behavioral Therapy for Insomnia Plus Antidepressant Medications: A Report From the TRIAD Study. Journal of Clinical Sleep Medicine, 2019, 15, 573-580.	2.6	20
42	The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nature Reviews Drug Discovery, 2019, 18, 82-84.	46.4	52
43	Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. Journal of Sleep Research, 2019, 28, e12782.	3.2	39
44	Obstructive Sleep Apnea in Pregnant Women: A Review of Pregnancy Outcomes and an Approach to Management. Anesthesia and Analgesia, 2018, 127, 1167-1177.	2.2	49
45	<italic>In Vitro</italic> Evaluation of an Injectable EEG/ECG Sensor for Wireless Monitoring of Hibernation in Endangered Animal Species. IEEE Sensors Journal, 2018, 18, 798-808.	4.7	4
46	The relationship of person-specific eveningness chronotype, greater seasonality, and less rhythmicity to suicidal behavior: A literature review. Journal of Affective Disorders, 2018, 227, 721-730.	4.1	50
47	Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. Journal of Clinical Psychiatry, 2018, 79, 35-48.	2.2	388
48	Screening extremely obese pregnant women for obstructive sleep apnea. American Journal of Obstetrics and Gynecology, 2018, 219, 613.e1-613.e10.	1.3	34
49	A review of the associations between obstructive sleep apnea and hypertensive disorders of pregnancy and possible mechanisms of disease. Sleep Medicine Reviews, 2018, 42, 37-46.	8.5	32
50	Treating insomnia in depression: Insomnia related factors predict long-term depression trajectories Journal of Consulting and Clinical Psychology, 2018, 86, 282-293.	2.0	53
51	Dr McClintock and Colleagues Reply. Journal of Clinical Psychiatry, 2018, 79, 17lr11851a.	2.2	0
52	Insomnia Patients With Objective Short Sleep Duration Have a Blunted Response to Cognitive Behavioral Therapy for Insomnia. Sleep, 2017, 40, .	1,1	44
53	National Sleep Foundation's sleep quality recommendations: first report. Sleep Health, 2017, 3, 6-19.	2.5	729
54	Segmented sleep in a nonelectric, smallâ€scale agricultural society in Madagascar. American Journal of Human Biology, 2017, 29, e22979.	1.6	43

#	Article	IF	Citations
55	Should Internet Cognitive Behavioral Therapy for Insomnia Be the Primary Treatment Option for Insomnia?. JAMA Psychiatry, 2017, 74, 15.	11.0	4
56	Pilot prospective study of post-surgery sleep and EEG predictors of post-operative delirium. Clinical Neurophysiology, 2017, 128, 1421-1425.	1.5	38
57	Double-Blind, Placebo-Controlled, Crossover Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia. Sleep, 2017, 40, .	1.1	3
58	Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials. American Journal of Geriatric Psychiatry, 2017, 25, 791-802.	1.2	51
59	Clinical profile of suvorexant for the treatment of insomnia over 3Âmonths in women and men: subgroup analysis of pooled phase-3 data. Psychopharmacology, 2017, 234, 1703-1711.	3.1	13
60	Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. International Journal of Neuropsychopharmacology, 2017, 20, 613-618.	2.1	18
61	Cognitive Behavioral Insomnia Therapy for Those With Insomnia and Depression: A Randomized Controlled Clinical Trial. Sleep, 2017, 40, .	1.1	128
62	Hypnotic Medications and Suicide: Risk, Mechanisms, Mitigation, and the FDA. American Journal of Psychiatry, 2017, 174, 18-25.	7.2	96
63	Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study. Journal of Clinical Sleep Medicine, 2017, 13, 205-213.	2.6	6
64	Pharmacologic Treatment of Insomnia. , 2017, , 842-854.e5.		1
65	Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine, 2017, 13, 307-349.	2.6	864
66	Unipolar Major Depression., 2017,, 1352-1362.e5.		5
67	Anxiety Disorders and Posttraumatic Stress Disorder. , 2017, , 1341-1351.e5.		4
68	Shedding light to sleep studies. , 2017, , .		2
69	Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials. Journal of Clinical Sleep Medicine, 2016, 12, 1215-1225.	2.6	51
70	The sleep effects of lurasidone: a placeboâ€controlled crossâ€over study using a 4â€h phaseâ€odvance model of transient insomnia. Human Psychopharmacology, 2016, 31, 206-216.	1.5	9
71	Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale. Trends in Pharmacological Sciences, 2016, 37, 933-944.	8.7	98
72	Hibernation in a primate: does sleep occur?. Royal Society Open Science, 2016, 3, 160282.	2.4	23

#	Article	IF	CITATIONS
73	Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biological Psychiatry, 2016, 80, 84-86.	1.3	2
74	Sleep Medications and Women: a Review of Issues to Consider for Optimizing the Care of Women with Sleep Disorders. Current Sleep Medicine Reports, 2016, 2, 218-222.	1.4	5
75	Shining evolutionary light on human sleep and sleep disorders. Evolution, Medicine and Public Health, 2016, 207-243.	2.5	78
76	Sleep and Mood: Chicken or Egg?. Biological Psychiatry, 2016, 80, 810-811.	1.3	3
77	Sleep disturbances in adolescents with ADHD: A systematic review and framework for future research. Clinical Psychology Review, 2016, 50, 159-174.	11.4	83
78	Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials. Depression and Anxiety, 2016, 33, 895-906.	4.1	123
79	Objective but Not Subjective Short Sleep Duration Associated with Increased Risk for Hypertension in Individuals with Insomnia. Sleep, 2016, 39, 1037-1045.	1.1	133
80	Sequential psychological and pharmacological therapies for comorbid and primary insomnia: study protocol for a randomized controlled trial. Trials, 2016, 17, 118.	1.6	8
81	Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials. Biological Psychiatry, 2016, 79, 136-148.	1.3	201
82	Efficacy of Cognitive-Behavioral Therapy for Insomnia Combined With Antidepressant Pharmacotherapy in Patients With Comorbid Depression and Insomnia. Journal of Clinical Psychiatry, 2016, 77, e1316-e1323.	2.2	106
83	Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder. primary care companion for CNS disorders, The, 2016, 18, .	0.6	8
84	Insomnia disorder. Nature Reviews Disease Primers, 2015, 1, 15026.	30.5	425
85	Pharmacologic Treatment of Insomnia. , 2015, , 2193-2204.		0
86	Individualized Low-Amplitude Seizure Therapy: Minimizing Current for Electroconvulsive Therapy and Magnetic Seizure Therapy. Neuropsychopharmacology, 2015, 40, 2076-2084.	5.4	33
87	Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial. Sleep Medicine, 2015, 16, 838-844.	1.6	24
88	Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. Brain Stimulation, 2015, 8, 787-794.	1.6	145
89	Restricting Benzodiazepines to Short-Term Prescription. JAMA Psychiatry, 2015, 72, 734.	11.0	9
90	New Developments in Insomnia Medications of Relevance to Mental Health Disorders. Psychiatric Clinics of North America, 2015, 38, 843-860.	1.3	10

#	Article	IF	CITATIONS
91	A multi-site randomized clinical trial to reduce suicidal ideation in suicidal adult outpatients with Major Depressive Disorder: Development of a methodology to enhance safety. Clinical Trials, 2015, 12, 189-198.	1.6	18
92	Current, Emerging, and Newly Available Insomnia Medications. Journal of Clinical Psychiatry, 2015, 76, e1045-e1045.	2.2	10
93	Effect of Armodafinil on Cortical Activity and Working Memory in Patients with Residual Excessive Sleepiness Associated with CPAP-Treated OSA: A Multicenter fMRI Study. Journal of Clinical Sleep Medicine, 2014, 10, 143-153.	2.6	8
94	The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: A double-blind, randomized, placebo-controlled trial. Schizophrenia Research, 2014, 160, 180-185.	2.0	50
95	Multifactorial Determinants of the Neurocognitive Effects of Electroconvulsive Therapy. Journal of ECT, 2014, 30, 165-176.	0.6	98
96	Obstructive sleep apnea and delirium: exploring possible mechanisms. Sleep and Breathing, 2014, 18, 19-29.	1.7	23
97	The sleep effects of tiagabine on the first night of treatment predict post-traumatic stress disorder response at three weeks. Journal of Psychopharmacology, 2014, 28, 457-465.	4.0	8
98	Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. Journal of Affective Disorders, 2014, 168, 439-451.	4.1	43
99	Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2014, 13, 461-471.	10.2	437
100	Therapeutic approaches for shankopathies. Developmental Neurobiology, 2014, 74, 123-135.	3.0	25
101	A Randomized, Double-Blind, Placebo-Controlled Trial of Eszopiclone for the Treatment of Insomnia in Patients with Chronic Low Back Pain. Sleep, 2014, 37, 1053-1060.	1.1	32
102	Towards injectable biophotonic sensors for physiological monitoring of animals. , 2014, , .		6
103	Comparison of diary-derived bladder and sleep measurements across OAB individuals, primary insomniacs, and healthy controls. International Urogynecology Journal, 2013, 24, 501-508.	1.4	6
104	Optimizing the Pharmacologic Treatment of Insomnia. Sleep Medicine Clinics, 2013, 8, 333-350.	2.6	43
105	Left dorsolateral prefrontal transcranial magnetic stimulation (TMS): Sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder. Psychiatry Research, 2013, 205, 67-73.	3.3	25
106	Review of the histamine system and the clinical effects of H1 antagonists: Basis for a new model for understanding the effects of insomnia medications. Sleep Medicine Reviews, 2013, 17, 263-272.	8.5	83
107	Topography of seizures induced by electroconvulsive therapy and magnetic seizure therapy. , 2013, , .		2
108	Novel Sublingual Low-Dose Zolpidem Tablet Reduces Latency to Sleep Onset following Spontaneous Middle-of-the-Night Awakening in Insomnia in a Randomized, Double-Blind, Placebo-Controlled, Outpatient Study. Sleep, 2013, 36, 189-196.	1.1	40

#	Article	IF	CITATIONS
109	Does Physiological Hyperarousal Enhance Error Rates among Insomnia Sufferers?. Sleep, 2013, 36, 1179-1186.	1.1	30
110	The Relationship of Sleep with Temperature and Metabolic Rate in a Hibernating Primate. PLoS ONE, 2013, 8, e69914.	2.5	22
111	The Consensus Sleep Diary: Standardizing Prospective Sleep Self-Monitoring. Sleep, 2012, 35, 287-302.	1.1	1,404
112	Psychiatric Disorders and Sleep. Neurologic Clinics, 2012, 30, 1389-1413.	1.8	275
113	REM Sleep Bout Duration and Frequency in PTSD. Journal of Aggression, Maltreatment and Trauma, 2012, 21, 67-76.	1.4	7
114	A WASO sub-group analysis of a 6-month study of eszopiclone 3mg. Sleep Medicine, 2012, 13, 691-696.	1.6	9
115	Comparison of polysomnographic data in age-, sex- and Axis I psychiatric diagnosis matched HIV-seropositive and HIV-seronegative Insomnia Patients. Clinical Neurophysiology, 2012, 123, 2402-2405.	1.5	10
116	Sleep in Mood Disorders. , 2012, , 675-681.		1
117	Obstructive Sleep Apnea and Incidence of Postoperative Delirium after Elective Knee Replacement in the Nondemented Elderly. Anesthesiology, 2012, 116, 788-796.	2.5	165
118	Loop Diuretics Have Anxiolytic Effects in Rat Models of Conditioned Anxiety. PLoS ONE, 2012, 7, e35417.	2.5	24
119	How the Circadian Rhythm Affects Sleep, Wakefulness, and Overall Health. Journal of Clinical Psychiatry, 2012, 73, e05.	2.2	8
120	Eszopiclone Treatment for Insomnia. primary care companion for CNS disorders, The, 2012, 14, .	0.6	13
121	Shift Work Disorder Case Studies. Journal of Clinical Psychiatry, 2012, 73, e25.	2.2	1
122	Repetitive Transcranial Magnetic Stimulation of the Superior Frontal Gyrus Modulates Craving for Cigarettes. Biological Psychiatry, 2011, 70, 794-799.	1.3	122
123	Insomnia is frequent in schizophrenia and associated with night eating and obesity. Schizophrenia Research, 2011, 133, 238-243.	2.0	104
124	The Association of Fatigue with Depression and Insomnia in HIV-Seropositive Patients: A Pilot Study. Sleep, 2011, 34, 1723-1726.	1.1	31
125	Pharmacologic Treatment., 2011,, 916-930.		2
126	Efficacy and Safety of Doxepin 3 and 6 mg in a 35-day Sleep Laboratory Trial in Adults with Chronic Primary Insomnia. Sleep, 2011, 34, 1433-42.	1.1	98

#	Article	IF	Citations
127	Should we be anxious when assessing anxiety using the Beck Anxiety Inventory in clinical insomnia patients?. Journal of Psychiatric Research, 2011, 45, 1243-1249.	3.1	37
128	Testing the Reliability and Validity of DSM-IV-TR and ICSD-2 Insomnia Diagnoses. Archives of General Psychiatry, 2011, 68, 992.	12.3	109
129	Pharmacological Advances in the Treatment of Insomnia. Current Pharmaceutical Design, 2011, 17, 1471-1475.	1.9	81
130	Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep, 2010, 33, 1553-1561.	1.1	159
131	Sleep EEG Predictors and Correlates of the Response to Cognitive Behavioral Therapy for Insomnia. Sleep, 2010, 33, 669-677.	1.1	73
132	A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Eszopiclone 2 mg on Sleep/Wake Function in Older Adults with Primary and Comorbid Insomnia. Sleep, 2010, 33, 225-234.	1.1	75
133	Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation, 2010, 3, 187-199.	1.6	130
134	Sleep–wake functioning along the cancer continuum: focus group results from the Patientâ€Reported Outcomes Measurement Information System (PROMIS [®]). Psycho-Oncology, 2010, 19, 1086-1093.	2.3	23
135	In Vivo Evidence of the Specificity of Effects of GABAA Receptor Modulating Medications. Sleep, 2010, 33, 859-860.	1.1	6
136	Antidepressant and Antipsychotic Drugs. Sleep Medicine Clinics, 2010, 5, 571-589.	2.6	27
137	Detrusor Overactivity Persisting at Night and Preceding Nocturia in Patients With Overactive Bladder Syndrome: A Nocturnal Cystometrogram and Polysomnogram Study. Journal of Urology, 2010, 184, 623-628.	0.4	23
138	Using difficulty resuming sleep to define nocturnal awakenings. Sleep Medicine, 2010, 11, 236-241.	1.6	34
139	A Double-Blind, Placebo-Controlled Study of Armodafinil for Excessive Sleepiness in Patients With Treated Obstructive Sleep Apnea and Comorbid Depression. Journal of Clinical Psychiatry, 2010, 71, 32-40.	2.2	28
140	The Effect of Vestibular Stimulation in a Four-Hour Sleep Phase Advance Model of Transient Insomnia. Journal of Clinical Sleep Medicine, 2010, 06, 315-321.	2.6	29
141	Treatment of Insomnia in Depressed Insomniacs: Effects on Health-related Quality of Life, Objective and Self-Reported Sleep, and Depression. Journal of Clinical Sleep Medicine, 2010, 06, 322-329.	2.6	64
142	Benzodiazepine Receptor Agonists: Indications, Efficacy, and Outcome. Medical Psychiatry, 2010, , 375-386.	0.2	1
143	The effect of vestibular stimulation in a four-hour sleep phase advance model of transient insomnia. Journal of Clinical Sleep Medicine, 2010, 6, 315-21.	2.6	12
144	Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. Journal of Clinical Sleep Medicine, 2010, 6, 322-9.	2.6	31

#	Article	IF	Citations
145	The Treatment of Primary Insomnia. CNS Spectrums, 2009, 14, 6-10.	1.2	6
146	Assessing depression symptoms in those with insomnia: An examination of the beck depression inventory second edition (BDI-II). Journal of Psychiatric Research, 2009, 43, 576-582.	3.1	80
147	A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice. Sleep Medicine Reviews, 2009, 13, 265-274.	8.5	137
148	Daily Left Prefrontal Repetitive Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: Clinical Predictors of Outcome in a Multisite, Randomized Controlled Clinical Trial. Neuropsychopharmacology, 2009, 34, 522-534.	5.4	272
149	The Pharmacologic Management of Insomnia in Patients with HIV. Journal of Clinical Sleep Medicine, 2009, 05, 251-262.	2.6	35
150	The pharmacologic management of insomnia in patients with HIV. Journal of Clinical Sleep Medicine, 2009, 5, 251-62.	2.6	15
151	It Is Time to Take a Stand for Medical Research and Against Terrorism Targeting Medical Scientists. Biological Psychiatry, 2008, 63, 725-727.	1.3	65
152	Modeling slow-wave activity dynamics: Does an exponentially dampened periodic function really fit a single night of normal human sleep?. Clinical Neurophysiology, 2008, 119, 2753-2761.	1.5	8
153	Measuring sleep quality. Sleep Medicine, 2008, 9, S10-S17.	1.6	386
154	Eszopiclone Coadministered With Escitalopram in Patients With Insomnia and Comorbid Generalized Anxiety Disorder. Archives of General Psychiatry, 2008, 65, 551.	12.3	145
155	Sleep Disturbance in Psychiatric Disorders: Effects on Function and Quality of Life in Mood Disorders, Alcoholism, and Schizophrenia. Annals of Clinical Psychiatry, 2008, 20, 39-46.	0.6	108
156	Long-Term Efficacy and Safety of Zolpidem Extended-Release 12.5 mg, Administered 3 to 7 Nights Per Week for 24 Weeks, in Patients With Chronic Primary Insomnia: A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study. Sleep, 2008, 31, 79-90.	1.1	211
157	Psychomotor Performance Defcits and Their Relation to Prior Nights' Sleep Among Individuals with Primary Insomnia. Sleep, 2008, 31, 599-607.	1.1	157
158	Effects of antipsychotic medications on sleep in schizophrenia. International Clinical Psychopharmacology, 2008, 23, 150-160.	1.7	88
159	Report of Two Cases Where Sleep Related Eating Behavior Occurred With the Extended-Release Formulation but Not the Immediate-Release Formulation of a Sedative-Hypnotic Agent. Journal of Clinical Sleep Medicine, 2008, 04, 155-156.	2.6	38
160	Bupropion HCL and Sleep in Patients with Depression. Current Psychiatry Reviews, 2007, 3, 123-128.	0.9	14
161	Associations of a Regulatory Polymorphism of Monoamine Oxidase-A Gene Promoter (MAOA-uVNTR) With Symptoms of Depression and Sleep Quality. Psychosomatic Medicine, 2007, 69, 396-401.	2.0	72
162	Sleep Quality Varies as a Function of 5-HTTLPR Genotype and Stress. Psychosomatic Medicine, 2007, 69, 621-624.	2.0	93

#	Article	IF	Citations
163	The Use of Prazosin for the Treatment of Trauma Nightmares and Sleep Disturbance in Combat Veterans with Post-Traumatic Stress Disorder. Biological Psychiatry, 2007, 61, 925-927.	1.3	31
164	Nightly Treatment of Primary Insomnia With Eszopiclone for Six Months: Effect on Sleep, Quality of Life, and Work Limitations. Sleep, 2007, 30, 959-968.	1.1	226
165	Psychotic disorder in a patient with central and extrapontine myelinolysis. Psychiatry and Clinical Neurosciences, 2007, 61, 320-322.	1.8	13
166	A Comparison of Rates of Residual Insomnia Symptoms Following Pharmacotherapy or Cognitive-Behavioral Therapy for Major Depressive Disorder. Journal of Clinical Psychiatry, 2007, 68, 254-260.	2.2	223
167	Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. Journal of Clinical Sleep Medicine, 2007, 3, 48-55.	2.6	60
168	Treating the health, quality of life, and functional impairments in insomnia. Journal of Clinical Sleep Medicine, 2007, 3, 63-72.	2.6	53
169	Psychiatric Comorbidity: The Case for Treating Insomnia. Sleep Medicine Clinics, 2006, 1, 359-365.	2.6	9
170	Sleep and Psychiatric Disorders: Future Directions. Psychiatric Clinics of North America, 2006, 29, 1115-1130.	1.3	39
171	Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder. Biological Psychiatry, 2006, 59, 1052-1060.	1.3	432
172	Tiagabine Increases Slow-Wave Sleep in a Dose-Dependent Fashion Without Affecting Traditional Efficacy Measures in Adults With Primary Insomnia. Journal of Clinical Sleep Medicine, 2006, 02, 35-41.	2.6	50
173	Sleep and Residual Sedation After Administration of Zaleplon, Zolpidem, and Placebo During Experimental Middle-of-the-Night Awakening. Journal of Clinical Sleep Medicine, 2006, 02, 417-423.	2.6	40
174	RESPONSE TO DR. FINUCANE. Journal of the American Geriatrics Society, 2006, 54, 171-172.	2.6	4
175	Long-Term Pharmacotherapy in the Management of Chronic Insomnia. Journal for Nurse Practitioners, 2006, 2, S621-S632.	0.8	0
176	A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion, 2006, 22, 1633-1642.	1.9	86
177	Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. Journal of Clinical Sleep Medicine, 2006, 2, 35-41.	2.6	17
178	Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening. Journal of Clinical Sleep Medicine, 2006, 2, 417-23.	2.6	11
179	Behavioral Insomnia Therapy for Fibromyalgia Patients. Archives of Internal Medicine, 2005, 165, 2527.	3.8	275
180	The Effect of Insomnia Definitions, Terminology, and Classifications on Clinical Practice. Journal of the American Geriatrics Society, 2005, 53, S258-S263.	2.6	29

#	Article	IF	CITATIONS
181	An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Medicine, 2005, 6, 487-495.	1.6	218
182	Hypnotics Should be Considered for the Initial Treatment of Chronic Insomnia. Journal of Clinical Sleep Medicine, 2005, 01, 120-124.	2.6	10
183	The possibility of preventing functional impairment due to sleep loss by pharmacologically enhancing sleep. Sleep, 2005, 28, 16-7.	1.1	4
184	The Sustained 6-Month Efficacy of Eszopiclone in the Treatment of Chronic Insomnia. Sleep, 2004, 27, 346-347.	1.1	7
185	Depression and insomnia in women. Clinical Cornerstone, 2004, 6, S19-S28.	0.7	47
186	Case report: successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine. Psychopharmacology, 2004, 173, 227-228.	3.1	26
187	Long-Term, Non-Nightly Administration of Zolpidem in the Treatment of Patients With Primary Insomnia. Journal of Clinical Psychiatry, 2004, 65, 1128-1137.	2.2	125
188	Introduction: Definitions, measurements, and management in insomnia. Journal of Clinical Psychiatry, 2004, 65 Suppl 8, 5-7.	2.2	0
189	The changing perspective on chronic insomnia management. Journal of Clinical Psychiatry, 2004, 65 Suppl 8, 20-5.	2.2	15
190	Panel discussion: changing how we think about insomnia. Journal of Clinical Psychiatry, 2004, 65 Suppl 8, 44-6.	2.2	0
191	Insomnia in women. Clinical Cornerstone, 2003, 5, 41-50.	0.7	69
192	Subtyping primary insomnia: is sleep state misperception a distinct clinical entity?. Sleep Medicine Reviews, 2003, 7, 203-214.	8.5	152
193	Comparison of Seizure Duration, Ictal EEG, and Cognitive Effects of Ketamine and Methohexital Anesthesia With ECT. Journal of Neuropsychiatry and Clinical Neurosciences, 2003, 15, 27-34.	1.8	94
194	Sustained Efficacy of Eszopiclone Over 6 Months of Nightly Treatment: Results of a Randomized, Double-Blind, Placebo-Controlled Study in Adults with Chronic Insomnia. Sleep, 2003, 26, 793-799.	1.1	629
195	Comparison of Seizure Duration, Ictal EEG, and Cognitive Effects of Ketamine and Methohexital Anesthesia With ECT. Journal of Neuropsychiatry and Clinical Neurosciences, 2003, 15, 27-34.	1.8	22
196	NREM Sleep EEG Frequency Spectral Correlates of Sleep Complaints in Primary Insomnia Subtypes. Sleep, 2002, , .	1.1	94
197	NREM sleep EEG frequency spectral correlates of sleep complaints in primary insomnia subtypes. Sleep, 2002, 25, 630-40.	1.1	225
198	Multichannel electroencephalographic analyses via dynamic regression models with time-varying lag-lead structure. Journal of the Royal Statistical Society Series C: Applied Statistics, 2001, 50, 95-109.	1.0	31

#	Article	IF	Citations
199	Treatment of the Modal Patient: Does One Size Fit Nearly All?. Journal of ECT, 2001, 17, 219-221.	0.6	5
200	Prediction of the Utility of a Switch from Unilateral to Bilateral ECT in the Elderly Using Treatment 2 lctal EEG Indices. Journal of ECT, 2000, 16, 327-337.	0.6	25
201	The Development and Retrospective Testing of an Electroencephalographic Seizure Quality–Based Stimulus Dosing Paradigm With ECT. Journal of ECT, 2000, 16, 338-349.	0.6	24
202	EEG effects of ECT: Implications for rTMS. Depression and Anxiety, 2000, 12, 157-165.	4.1	29
203	Stationarity and redundancy of multichannel EEG data recorded during generalized tonic-clonic seizures. Brain Topography, 2000, 12, 187-200.	1.8	16
204	ECT Stimulus Intensity: Are Present ECT Devices Too Limited?. American Journal of Psychiatry, 2000, 157, 963-967.	7.2	49
205	Evaluation and Comparison of EEG Traces: Latent Structure in Nonstationary Time Series. Journal of the American Statistical Association, 1999, 94, 1083-1095.	3.1	58
206	New methods of time series analysis of non-stationary EEG data: eigenstructure decompositions of time varying autoregressions. Clinical Neurophysiology, 1999, 110, 2197-2206.	1.5	47
207	Evaluation and Comparison of EEG Traces: Latent Structure in Nonstationary Time Series. Journal of the American Statistical Association, 1999, 94, 375-387.	3.1	23
208	EEG Correlates of the Response to ECT. Journal of ECT, 1999, 15, 27???38.	0.6	26
209	2. ECT and Anticonvulsant Medications. Journal of ECT, 1999, 15, 104.	0.6	0
210	3. Magnetic Resonance Spectroscopic Correlates of the Response to ECT. Journal of ECT, 1999, 15, 103.	0.6	0
211	Evaluation and Comparison of EEG Traces: Latent Structure in Nonstationary Time Series. Journal of the American Statistical Association, 1999, 94, 1083.	3.1	11
212	Evaluation and Comparison of EEG Traces: Latent Structure in Nonstationary Time Series. Journal of the American Statistical Association, 1999, 94, 375.	3.1	3
213	Zolpidem for Persistent Insomnia in SSRI-Treated Depressed Patients. Journal of Clinical Psychiatry, 1999, 60, 668-676.	2.2	155
214	Sleep in peri-menopausal and post-menopausal women. Sleep Medicine Reviews, 1998, 2, 243-253.	8.5	108
215	Low-Dimensional Chaos in Bipolar Disorder?. Archives of General Psychiatry, 1998, 55, 275.	12.3	13
216	Changes in Seizure Threshold Over the Course of Electroconvulsive Therapy Affect Therapeutic Response and Are Detected by Ictal EEG Ratings. Journal of Neuropsychiatry and Clinical Neurosciences, 1998, 10, 178-186.	1.8	87

#	Article	IF	Citations
217	The Use of Flumazenil in the Anxious and Benzodiazepine-Dependent ECT Patient. Journal of ECT, 1998, 14, 5???14.	0.6	35
218	The Clinical Utility of Ictal EEG Seizure Adequacy Models. Psychiatric Annals, 1998, 28, 30-35.	0.1	24
219	The largest Lyapunov exponent of the EEG during ECT seizures as a measure of ECT seizure adequacy. Electroencephalography and Clinical Neurophysiology, 1997, 103, 599-606.	0.3	32
220	Effect of ECT treatment number on the ictal EEG. Psychiatry Research, 1996, 62, 179-189.	3.3	29
221	A comparison of EEG signal dynamics in waking, after anesthesia induction and during electroconvulsive therapy seizures. Electroencephalography and Clinical Neurophysiology, 1996, 99, 129-140.	0.3	19
222	The Empirical Identification of Insomnia Subtypes: A Cluster Analytic Approach. Sleep, 1996, , .	1.1	12
223	Ambulatory Cassette Polysomnography. Journal of Clinical Neurophysiology, 1995, 12, 302-309.	1.7	4
224	Seizure threshold in electroconvulsive therapy (ECT) II. The anticonvulsant effect of ECT. Biological Psychiatry, 1995, 37, 777-788.	1.3	120
225	Seizure threshold in electroconvulsive therapy: I. Initial seizure threshold. Biological Psychiatry, 1995, 37, 713-720.	1.3	138
226	The effects of ECT stimulus dose and electrode placement on the Ictal electroencephalogram: An intraindividual crossover study. Biological Psychiatry, 1993, 34, 759-767.	1.3	89
227	Low-Frequency Ictal EEG Activity and ECT Therapeutic Impact. Convulsive Therapy, 1993, 9, 220-224.	0.1	0
228	Ambulatory Polysomnography. Journal of Clinical Neurophysiology, 1992, 9, 68-77.	1.7	27
229	EEG evidence of more "intense―seizure activity with bilateral ECT. Biological Psychiatry, 1992, 31, 617-621.	1.3	34
230	The Monitoring and Management of Electrically Induced Seizures. Psychiatric Clinics of North America, 1991, 14, 845-869.	1.3	64
231	Geriatric psychopharmacology: an overview. , 0, , 327-331.		0